Jazz Pharmaceuticals plc (NASDAQ:JAZZ) went down by -6.91% from its latest closing price compared to the recent 1-year high of $169.98. The company’s stock price has collected -8.98% of loss in the last five trading sessions. The Wall Street Journal reported on 07/05/21 that Midsize Pharmaceutical Firms Are the Industry’s Big Deal Makers
Is It Worth Investing in Jazz Pharmaceuticals plc (NASDAQ :JAZZ) Right Now?
Plus, the 36-month beta value for JAZZ is at 0.68. Opinions of the stock are interesting as 14 analysts out of 18 who provided ratings for Jazz Pharmaceuticals plc declared the stock was a “buy,” while 2 rated the stock as “overweight,” 2 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $200.24, which is $63.94 above the current price. JAZZ currently public float of 61.10M and currently shorts hold a 4.54% ratio of that float. Today, the average trading volume of JAZZ was 489.01K shares.
JAZZ’s Market Performance
JAZZ stocks went down by -8.98% for the week, with a monthly drop of -12.01% and a quarterly performance of -7.56%, while its annual performance rate touched 7.15%. The volatility ratio for the week stands at 3.53% while the volatility levels for the past 30 days are set at 2.67% for Jazz Pharmaceuticals plc. The simple moving average for the period of the last 20 days is -10.34% for JAZZ stocks with a simple moving average of -7.26% for the last 200 days.
Analysts’ Opinion of JAZZ
Many brokerage firms have already submitted their reports for JAZZ stocks, with UBS repeating the rating for JAZZ by listing it as a “Buy.” The predicted price for JAZZ in the upcoming period, according to UBS is $194 based on the research report published on June 14th of the current year 2022.
Goldman, on the other hand, stated in their research note that they expect to see JAZZ reach a price target of $196, previously predicting the price at $202. The rating they have provided for JAZZ stocks is “Neutral” according to the report published on April 06th, 2022.
Goldman gave a rating of “Buy” to JAZZ, setting the target price at $198 in the report published on November 19th of the previous year.
JAZZ Trading at -11.16% from the 50-Day Moving Average
After a stumble in the market that brought JAZZ to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -18.91% of loss for the given period.
Volatility was left at 2.67%, however, over the last 30 days, the volatility rate increased by 3.53%, as shares sank -12.43% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -11.43% lower at present.
During the last 5 trading sessions, JAZZ fell by -8.98%, which changed the moving average for the period of 200-days by +12.34% in comparison to the 20-day moving average, which settled at $152.76. In addition, Jazz Pharmaceuticals plc saw 8.19% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at JAZZ starting from Larkin Finbar, who sale 63 shares at the price of $150.00 back on Sep 07. After this action, Larkin Finbar now owns 19,606 shares of Jazz Pharmaceuticals plc, valued at $9,450 using the latest closing price.
COZADD BRUCE C, the Chairman & CEO of Jazz Pharmaceuticals plc, sale 7,703 shares at $153.18 during a trade that took place back on Sep 06, which means that COZADD BRUCE C is holding 353,311 shares at $1,179,970 based on the most recent closing price.
Stock Fundamentals for JAZZ
Current profitability levels for the company are sitting at:
- +12.90 for the present operating margin
- +68.76 for the gross margin
The net margin for Jazz Pharmaceuticals plc stands at -10.65. Equity return is now at value -1.40, with -0.40 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 3.17.